Ligand Pharmaceuticals Incorporated Stock News

Palvella Therapeutics, Inc., a Wayne, PA – based rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases wit

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule io

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Se

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and.

Stock picking is becoming critical. Focus on healthcare and technology. Here are the top stocks to buy now.

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

The

CASI is focused on developing and commercialising drugs for the Chinese market most notably within the field of hematology/oncology using an innovative in-licen

Tarveda reports complete data from the Phase 1 dose escalation portion of a Phase 1/2a study of PEN-866 in advanced solid tumor malignancies.

Benzinga’s Take Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development....

It is now my pleasure to turn today's program over to Patrick O'Brien, SVP, Investor Relations at Ligand's Pharmaceuticals. Speaking for Ligand today will be John Higgins, CEO; Matt Foehr, COO; and M